You just read:

Avelas Biosciences Doses First Patient in Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

News provided by

Avelas Biosciences, Inc.

Aug 03, 2017, 13:30 ET